A bone regeneration membrane containing resorbable or degradable, polymeric and/or polymeric-ceramic material with a glass transition temperature in the range of -30° to +200°C

The novel membrane can be used for the spontaneous regeneration of bone and for the improved application of autologous or allogenic graft materials and therapeutic agents.

Patent
   5676699
Priority
Sep 10 1990
Filed
May 07 1993
Issued
Oct 14 1997
Expiry
Oct 14 2014
Assg.orig
Entity
Large
159
24
EXPIRED
1. A thin, resorbable bone regeneration membrane containing interconnected micropores and having a thickness between 0.05 mm and 5.0 mm, said membrane comprising resorbable or degradable polymeric material wherein the glass transition temperature of said polymeric material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100∅
30. A thin, resorbable bone regeneration membrane containing interconnected micropores and having a thickness between 0.05 mm and 5.0 mm, said membrane consisting of resorbable or degradable polymeric material having a glass transition temperature in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100∅
25. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane further contains antineoplastic agents.
24. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane further contains antiosteomyelitis agents.
23. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, and further comprising reinforcement including resorbable and/or degradable fibers.
27. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane further contains osteoinductive agents of autogenic, allogenic, xenogenic, or synthetic origin.
26. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane further contains osteoconductive agents of autogenic, allogenic, xenogenic, or synthetic origin.
28. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane is formed in a tubular form with a longitudinal slit adapted to form semi-occlusive fits at the two extremities of the tube formed by said membrane for fixation to bones.
29. A bone regeneration membrane comprising resorbable or degradable polymeric and/or polymeric-ceramic material wherein the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to 200°C and the molecular weight distribution of said polymeric material is in the range of 1.2 to 100.0, said membrane having interconnected micropores therein, wherein said membrane is formed in a tubular form with a longitudinal slit having ends shaped to form semi-occlusive fits over cortical bone ends and within medullary canals of long or tubular bones.
2. A membrane according to claim 1 where said glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of body temperature to +90°C
3. A membrane according to claim 1 wherein at least 90 percent of said micropores have a diameter in the range of 0.1 to 5.0 μm.
4. A membrane according to claim 1 wherein at least 90 weight percent of said polymeric material has a molecular weight in the range of 5,000 to 1,000,000.
5. A membrane according to claim 1 wherein at least 90 weight percent of said polymeric material has a molecular weight in the range of 25,000 to 150,000.
6. A membrane according to claim 5, wherein said polymeric material is selected from the group consisting of highly purified polyhydroxyacids, polysaccharides, polyamines, polyaminoacids, polyorthoesters, polyanhydrides, collagen, and composites thereof with tricalcium phosphate and/or hydroxyapatite.
7. A membrane according to claim 1, which further contains antibiotic agents.
8. A membrane according to claim 1, which has a curved surface.
9. A membrane according to claim 8, wherein said curved surface is capable of being adapted to match the dimensions of the bone.
10. A membrane according to claim 16, which has a shape memory.
11. A membrane according to claim 9, wherein said membrane is formed into a tubular form with a longitudinal slit.
12. A membrane according to claim 11 comprising a sheet for use in surgical procedures, wherein said sheet is fashioned into a tubular form intraoperatively by the surgeon.
13. A membrane according to claim 11, comprising a sheet rolled up to form a multilayer tube.
14. A membrane according to claim 2 wherein said glass transition temperature is in the range of +40°C to +70°C
15. A membrane according to claim 1 wherein at least 99 weight percent of said polymeric material has a molecular weight in the range of 5,000 to 1,000,000.
16. A membrane according to claim 1 and having a thickness between 0.2 mm and 3.0 mm.
17. A membrane according to claim 16 and having a thickness of between 0.4 mm and 1.5 mm.
18. A membrane according to claim 5 wherein at least 90 weight percent of said polymeric material has a molecular weight in the range of 30,000 to 70,000.
19. A membrane according to claim 8, wherein said membrane has a surface defined by the movement of a substantially straight line along a curved planar path.
20. A membrane according to claim 9 wherein said surface is cylindrical.
21. A membrane according to claim 12 wherein said tubular form is adapted to be modified intraoperatively by a surgeon applying said membrane to match the dimensions of the bone.
22. A membrane according to claim 1 wherein said polymeric material has a molecular weight distribution in the range of 1.9 to 2.5.

This application is a file wrapper continuation of application Ser. No. 580,180 filed on Sep. 10, 1990, now abandoned.

1. Field of the Invention

This invention relates to a bone regeneration membrane containing resorbable or degradable polymeric and/or polymeric-ceramic material.

Diaphyseal bone loss results from high-energy trauma, infection, or resection performed for skeletal neoplasia. The numerous treatment modalities attest to the difficulty in obtaining reliable and satisfactory reconstitution of skeletal long bone defects. Methods for treating diaphyseal bone defects include: autologous cancellous or cortical bone grafts, autologous vascularized bone transplants and grafts, xenogenic bone grafts, allogenic bone grafts, hydroxyapatite and/or tricalcium phosphate ceramics implants, coral, natural polymers like collagen, synthetic polymers like polyethylene and polyglycolide, osteoinductive proteins such as bone morphogenetic protein, and bone transport techniques. All these methods have failed in producing predictable reconstruction of cortico-cancellous bone loss from diaphyseal segment of the human skeleton.

2. Description of the Prior Art

Various proposals have been made for the application of membranes containing resorbable or degradable polymeric material for bone regeneration purposes. These membranes degrade in the body over a period of time and may be absorbed by the bone or body tissues.

From an article of Magnusson, Batich and Collins, published in the J. Periodontol., Jan. 1988 pp. 1-5, it is known to utilize very thin membranes of unspecified porosity and consisting of low-molecular weight polylactic acid for the regeneration of the dental cementum.

It is also known from Dahlin, Linde, Gottlow and Nyman (Plastic and Reconstructive Surgery, May 1988, pp. 672-676) to use a porous polytetrafluoroethylene membrane for healing bone in the jaw.

It is further known from Farso-Nielsen, Karring and Gogolewski (IADR General Session, Mar. 7-11, 1990, Cincinnati, Ohio) to use elastic biodegradable polyurethane membranes of unspecified structure for healing bone defects in rabbits.

From Warrer, Karring, Nyman and Gogolewski (paper submitted to J.Periodontol. 1990) it is further known that the use of membranes consisting of unspecified polylactic acid or polyurethane polymers failed to produce regeneration of periodontal defects.

With all these prior art membranes of largely unspecified structure and chemistry clinical results are rather unpredictable and vary from author to author.

The present invention is intended to remedy these drawbacks, It solves the problem of how to design a membrane containing resorbable or degradable polymeric and/or polymeric-ceramic material having a well-defined structure and chemistry which--when properly fashioned and applied--will promote spontaneous human bone regeneration as well as improve the efficacy of adjunctive bone conductive and inductive substances.

Briefly described, the invention comprises a bone regeneration membrane containing resorbable or degradable polymeric and/or polymeric-ceramic material having a glass transition temperature in the range of -30° C. to 200°C, the membrane having micropores therein. At least 90 percent of the micropores have a diameter in the range of 0.001 to 50.0 μm and the overall porosity of the membrane is less than 90 percent.

The membrane advantage contains osteoconductive or osteoinductive agents of autogenic, allogenic, xenogenic or synthetic origin.

The polymeric or polymeric-ceramic material used for the membranes according to the invention must have the glass transition temperature in the range of -30° to +200°C, Preferably the glass transition temperature of said polymeric and/or polymeric-ceramic material is in the range of +10° to +90°C and most preferably between +30° to +70°C

Glass transition temperature has surprisingly turned out to be of great importance, since application of membranes made of low glass transition temperature polymeric materials to bone defects have resulted in undesired external callus formation.

Chemically the membrane is prepared from highly purified resorbable and/or degradable polymers and/or polymer-ceramics such as polyhydroxyacids, polysaccharides, polyamines, polyaminoacids, polyorthoesters, polyanhydrides, collagen or composites thereof with tricalcium phosphate and/or hydroxyapatite, whereby preferably at least 90 weight percent of the material has a molecular weight in the range of 5,000 to 1,000,000, preferably in the range of 25,000 to 150,000 and most preferably in the range of 30,000 to 70,000.

In terms of molecular weight distribution, (or polydispersity) the polymeric and/or polymeric-ceramic material should have a polydispersity in the range of 1.2 to 100.0, preferably in the range of 1.9 to 2.5.

Structurally the membrane is generally thin and preferably microporous. The thickness of the membrane can be controlled to meet structural demands of the proposed implantation site, but should range between 0.05 to 5.0 mm, preferably between 0.2 to 3.0 mm and most preferably between 0.4 to 1.5 mm. The specific pore size, shape and structure to be selected for a certain application is variable to a large extent, whereby at least 90 percent of the micropores present in the polymeric material should have a diameter below 500 μm, preferably in the range of 0.01 to 50.0 μm and most preferably in the range of 0.1 to 5 μm. What is essential is that the micropores are permeable for nutritional fluids. Therefore the micropores within the membrane should be preferably interconnected to allow liquids penetration and circulation.

A membrane having the structural and chemical features according to the invention exhibits a resorption rate in vivo in the range from 2 weeks to 1 year and longer. The resorption rate can be adjusted to a desired value (e.g. to over one year for the treatment of large defects) by altering the polymer molecular weight, the polymer chain orientation and crystallinity, physical structure, chemical composition, presence and extent of voids, additives and so on.

The membranes can be used in a planar form, but generally are prefashioned or modified intraoperatively by the surgeon to conform to a curved surface, preferably a rectilinear surface. Most suitable are membranes with an adaptable surface, preferably a cylindrical surface, which most preferably is of tubular (circular cylinder) form.

In a preferred embodiment the membrane according to the invention is shaped in tubular form, preferably with a longitudinal slit to allow variability of the tubular diameter over a wide range. The diameter of the tubular membrane should match the dimensions of the bone to be treated, e.g. 4.0 to 50.0 mm for tibia reconstructions. A thin membrane of e.g. 0.1 mm thickness can also be rolled up either pre- or intraoperatively to form a final tubular implant with a wall thickness of e.g. 3.1 mm.

In a preferred embodiment the overlapping, intersected tubular membrane according to the invention provides semi-occlusive fits at the two extremities of the tube for better external adaptation to the cortical bone ends and/or internal adaptation within medullary canals of long or tubular bones.

It is of importance that the internal membrane tube to be inserted into an intramedullary canal is formed on a mandrel which has an external diameter at least 1.1 to 3.0 times bigger than the diameter of the intramedullary canal. The external membrane tube should be formed on a mandrel which has an external diameter which is at least 1.1 to 3.0 times smaller than the external diameter of the bone. Due to its "shape memory" the tubular membrane can be easily placed and fit on the bone to be treated.

If two tubular membranes are used (an external over the cortical bone ends and a internal within the medullary canal) they can either be used with or without spacers between the two tubular membranes. The two membranes can either be supplied preoperatively as a single unit (with interconnecting structures) or can be assembled intraoperatively by the surgeon. Accordingly one membrane is rolled in a tubular fashion to obtain a press fit into the medullary canal of both bone fragments, and a second membrane is rolled into a tube to form a semi-occlusive external sleeve, bridging the two bone fragment ends. The space between the two membranes forms a new artificial cortex that can be filled with a variety of therapeutic substances, such as autologous bone, allogenic bone, demineralized bone powder extracts, bone morphogenetic protein isolates, antibiotics, or antineoplastic drugs. The walls of the membranes can either be continuous or intersected longitudinally for better adaptation of the membrane on the bone. If necessary, the space between the inner and outer tubular membranes can be maintained in their relative position by means of spokes, ribs or other corrugated elements attached permanently, or inserted between the membrane tubes upon surgery.

The membrane tube can be used as a complete construction or only as a part of the construction (e.g. a half construction) depending on the bone defect to be treated.

The membranes according to the invention can be used for a variety of applications to span osseous defects that have been conventionally stabilized with an external fixator, intramedullary rod, or systems of plates and screws, of which the most important are listed below:

as a tissue separator which promotes and protects osseous regeneration;

for the treatment of osseous defects secondary to trauma, infection, neoplasm, or surgical resection;

as cortical spacer across bone defects;

as an osseous activity barrier that confines bone regeneration to desired regions and prevents the formation of synostosis, physeal bars, or ectopic bone;

as a spacer for skeletal resection, revision arthroplasty, or arthrodesis of human joints;

as a container for autologous or allogenic graft materials; and

as a combined bone grafting and/or drug delivery system.

The membrane according to the invention, therefore, offers a novel treatment that reliably promotes osseous healing with and without adjunctive therapies, while posing no toxic risks or requirements for extensive surgery for implantation or removal. The membrane can be preoperatively shaped and adjusted by the surgeon to conform and integrate with a wide range of anatomical defects and locations.

The advantages offered by the invention are mainly the following:

maintainance of a physical barrier that contains osseous activity of the host bone, while simultaneously protecting this osseous activity from nonosteogenic and interfering cell lines.

protection of the cortical and medullary canal osteogenic capacity from surrounding soft tissues and inflammatory reactions.

The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming part of this disclosure. For the better understanding of the invention, its operating advantages and specific objects attained by its use, reference should be had to the accompanying drawings, examples and descriptive matter in which are illustrated and described preferred embodiments of the invention.

In the drawings,

FIG. 1 is a simplified perspective view of a membrane in accordance with the invention;

FIG. 2 is a side elevation schematically illustrating technique for applying a membrane in accordance with the invention;

FIG. 3 is a side elevation schematically illustrating an application of membranes in the intermedullary canal as well as externally; and

FIG. 4 is an illustration of an application similar to FIG. 3 wherein the space between membranes is filled with autogenic cancellous bone graft.

The membranes according to the invention can be produced by any technique known to those skilled in the art, e.g. by solvent-casting, extrusion, injection-moulding, vacuum-forming, blowing, spraying, brushing, polymerization, compression-moulding, etc.

Two specific examples are given below:

Poly(L-lactide) with a viscosity-average molecular weight in the range of 15,000-700,000 Daltons were purified twice by dissolution in chloroform followed by precipitation with methanol. Polymers were dried under vacuum to constant weight and kept in a dessicator over molecular sieves. Microporous, resorbable membranes were prepared in the phase-reverse technique. Flat membranes were wetted in polar or nonpolar liquids and preshaped over mandrels of suitable shape, to fit the approximate diameter of the implantation site. The membranes were preshaped to the anatomy of the bone to be covered.

Wet membranes rolled up on the mandrels were covered with aluminium foil to protect them against unrolling and placed at 50°-150°C in the vacuum oven for 0.5-6.0 hours. After removal of the aluminium foil the membrane 1 had the configuration as shown in FIG. 1. Thanks to the longitudinal slit 2 parallel to its central axis 3 and its inherent shape memory the membrane was adaptable in diameter over a large extent to match bone ends of different sizes and diameters. The membrane produced according to this example had a glass transition temperature of +50°C, The pore size of the membrane was in the range of 0.1 to 1.0 μm and its thickness was 1.0 mm. Viscosity--average molecular weight of the polymeric membrane according to this example was 75,000, and its molecular weight distribution was 2.2.

The tubular membranes were used to cover a diphyseal defect of ten rabbits, Two months after surgery the canal created by the membrane according to this example was filled with osseous tissue.

Microporous resorbable membranes were prepared from poly(L-lactide) with a viscosity-average molecular weight of 15,000 to 100,000 Daltons according to the method of manufacture described in Example I.

The membrane produced according to this example had a glass transition temperature of 50°C and showed a porosity in the range of 10 to 50 μm and a thickness of 0.9 mm.

Numerous controlled experiments by the applicants have demonstrated that the novel membranes obtained by the described methods of manufacture promote bone growth in a reliable manner and further improve the efficacy of adjunctive bone conductive and inductive substances.

The membrane obtained by the method according to Example II was sterilized with ethylene oxide and implanted in 15 mature rabbits, to cover mid-diaphyseal defects of 10 mm created in the radius of a limb. An identical, but untreated defect on the other limb served as a control.

Within one week the membrane implants were filled with tissues that progressively differentiated into osseous tissue. By one month, further osseous formation had bridged 40 to 95% of the defect. New bone was formed within the inner canal of the polymeric membrane tube. In contrast, the control defects were occupied by overlying muscle and soft tissues.

The application of the membranes according to the invention is now further described by having reference to the drawings:

In a first application, shown in FIG. 2, a tubular membrane 1 was pulled over the aligned and correctly positioned extremities 4,5 of a fractured long bone 6 and affixed thereto by means of wires 7,8. Of course the membrane 1 can be affixed to the bone ends 4,5 by a variety of suitable means including external suture, metal or polymer screws, and/or plate and band combinations. The whole assembly was further fixed by means of an external fixator 9.

In a second application, shown in FIG. 3, prior to the fixation of the external membrane 1, a second tubular membrane 11 was previously inserted in the intramedullary canal 12, thereby forming a confined space 13, which as shown in FIG. 4 was filled with autogenic cancellous bone graft 14.

Gogolewski, Sylwester, Perren, Stephan M., Meinig, Richard P.

Patent Priority Assignee Title
10010432, Oct 22 2014 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
10016534, Nov 17 2008 PETVIVO HOLDINGS, INC Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
10022132, Dec 12 2013 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
10064740, Feb 06 2003 Depuy Synthes Products, LLC Intervertebral implant
10076342, Dec 12 2013 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
10105237, May 12 2009 Bullard Spine, LLC Multi-layer osteoinductive, osteogenic, and osteoconductive carrier
10111697, Sep 26 2003 DePuy Synthes Products, Inc. Device for delivering viscous material
10130489, Apr 12 2010 Globus Medical, Inc. Expandable vertebral implant
10130492, Oct 22 2014 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
10137003, Nov 16 2007 DePuy Synthes Products, Inc. Low profile intervertebral implant
10206781, May 13 2014 The University of Akron; Houston Methodist Hospital Modular device for preventing compression and instability in a segmental defect repair scaffold
10258472, Mar 31 2015 DEPUY SYNTHES PRODUCTS, INC Bone graft cage
10292822, Mar 31 2015 DePuy Synthes Products, Inc. Bone graft cage
10314717, Jan 12 2009 Globus Medical, Inc. Expandable vertebral prosthesis
10433976, Nov 07 2008 DePuy Synthes Products, Inc. Zero-profile interbody spacer and coupled plate assembly
10492922, Feb 19 2002 DePuy Synthes Products, Inc. Intervertebral implant
10492928, Apr 12 2010 Globus Medical, Inc. Angling inserter tool for expandable vertebral implant
10500053, Feb 28 2011 DEPUY SYNTHES PRODUCTS, INC Modular tissue scaffolds
10507110, Jun 13 2016 DEPUY SYNTHES PRODUCTS, INC Bone graft cage
10507117, Dec 21 2010 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
10512548, Feb 27 2006 DePuy Synthes Products, Inc. Intervertebral implant with fixation geometry
10531960, Nov 07 2008 DePuy Synthes Products, Inc. Zero-profile interbody spacer and coupled plate assembly
10543102, Nov 16 2007 DePuy Synthes Products, Inc. Low profile intervertebral implant
10603087, Jan 14 2008 Conventus Orthopaedics, Inc. Apparatus and methods for fracture repair
10660765, Feb 06 2003 DePuy Synthes Products, Inc. Intervertebral implant
10695181, Feb 16 2016 DEPUY SYNTHES PRODUCTS, INC Bone graft cage
10702394, Oct 22 2014 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
10898343, May 12 2009 Bullard Spine, LLC Multi-layer osteoinductive, osteogenic, and osteoconductive carrier
10918426, Jul 04 2017 CONVENTUS ORTHOPAEDICS, INC Apparatus and methods for treatment of a bone
11051944, Jun 13 2016 DePuy Synthes Products, Inc. Bone graft cage
11298243, Apr 12 2010 Globus Medical, Inc. Angling inserter tool for expandable vertebral implant
11399878, Jan 14 2008 Conventus Orthopaedics, Inc. Apparatus and methods for fracture repair
11399951, Jan 12 2009 Globus Medical, Inc. Expandable vertebral prosthesis
11458027, Dec 21 2010 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
11504240, Jun 04 2020 DEPUY SYNTHES PRODUCTS, INC Modular bone graft cage
11517444, Nov 07 2008 DePuy Synthes Products, Inc. Zero-profile interbody spacer and coupled plate assembly
11540927, Oct 22 2014 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
11596419, Mar 09 2017 FLOWER ORTHOPEDICS CORPORATION Plating depth gauge and countersink instrument
11612492, Nov 07 2008 DePuy Synthes Products, Inc. Zero-profile interbody spacer and coupled plate assembly
11696837, Feb 27 2006 DePuy Synthes Products, Inc. Intervertebral implant with fixation geometry
11793644, Feb 28 2011 DePuy Synthes Products, Inc. Modular tissue scaffolds
11819380, Oct 13 2016 Devices for tissue augmentation
11890371, Dec 26 2007 PETVIVO HOLDINGS, INC Biocompatible protein-based particles and methods thereof
5868746, Mar 01 1994 Biomet Manufacturing, LLC Method and apparatus for securing adjacent bone portions
6031148, Dec 06 1990 W L GORE & ASSOCIATES, INC Implantable bioabsorbable article
6083264, Jun 30 1998 McDonnell Douglas Corporation Implant material for replacing or augmenting living bone tissue involving thermoplastic syntactic foam
6146420, Dec 10 1997 Warsaw Orthopedic, Inc Osteogenic fusion device
6169046, Sep 10 1996 DIRECTOR-GENERAL OF NATIONAL INSTITUTE FOR RESEARCH IN INORGANIC MATERIALS Absorbable barrier membrane
6312467, Jul 18 1995 IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC Method of restructuring bone
6328765, Dec 03 1998 W L GORE & ASSOCIATES, INC Methods and articles for regenerating living tissue
6364909, Jul 18 1995 IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC Method of restructuring bone
6391059, Apr 07 1998 MacroPore, Inc. Membrane with tissue-guiding surface corrugations
6409764, Dec 03 1998 W L GORE & ASSOCIATES, INC Methods and articles for regenerating bone or peridontal tissue
6527810, Oct 01 1997 WRIGHT MEDICAL TECHNOLOGY, INC Bone substitutes
6565606, Sep 09 1998 Tigran Technologies AB Implant, method of making the same and use the same
6579533, Nov 30 1999 Bioretec Ltd Bioabsorbable drug delivery system for local treatment and prevention of infections
6613089, Oct 25 2000 Warsaw Orthopedic, Inc Laterally expanding intervertebral fusion device
6648916, Dec 10 1997 Warsaw Orthopedic, Inc Osteogenic fusion device
6719793, Jul 18 1995 Iowa State University Research Foundation, Inc. Method of restructuring bone
6736848, May 29 2001 Warsaw Orthopedic, Inc Method and apparatus for using formable polymers for orthopedic support
6758863, Oct 25 2000 VALVE HOLDINGS, L L C Vertically expanding intervertebral body fusion device
6780192, Oct 24 2000 Warsaw Orthopedic, Inc Osteogenic packing device and method
6855169, Feb 28 2001 Synthes USA, LLC Demineralized bone-derived implants
6977095, Oct 01 1997 WRIGHT MEDICAL TECHNOLOGY, INC Process for producing rigid reticulated articles
6986788, Jan 30 1998 Synthes USA, LLC Intervertebral allograft spacer
7115146, Mar 22 2000 Synthes USA, LLC Multipiece implants formed of bone material
7179293, Dec 10 1997 Warsaw Orthopedic, Inc. Osteogenic fusion device
7226482, Sep 01 2004 Synthes USA, LLC Multipiece allograft implant
7232464, Feb 19 2002 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
7250550, Oct 22 2004 WRIGHT MEDICAL TECHNOLOGY, INC Synthetic bone substitute material
7285135, Dec 10 1997 Warsaw Orthopedic, Inc. Osteogenic fusion device
7300465, Jan 30 1998 Synthes USA, LLC Intervertebral allograft spacer
7550011, Oct 24 2000 Warsaw Orthopedic, Inc. Osteogenic packing device and method
7601173, Sep 02 2003 Synthes USA, LLC Multipiece allograft implant
7608113, Feb 28 2001 Synthes USA, LLC Demineralized bone implants
7618456, Feb 19 2002 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
7674296, Apr 21 2005 Globus Medical Inc Expandable vertebral prosthesis
7732198, Oct 06 2003 Celgen AG Device for the regeneration of tissue, specifically bone regeneration by means of callus distraction
7740897, Oct 01 1997 Wright Medical Technology, Inc. Process for producing rigid reticulated articles
7753963, Feb 28 2001 Synthes USA, LLC Demineralized bone-derived implants
7754246, Sep 09 2005 Agnovos Healthcare, LLC Composite bone graft substitute cement and articles produced therefrom
7763079, Dec 10 1997 Warsaw Orthopedic, Inc Osteogenic fusion device
7766972, Oct 22 2004 Wright Medical Technology, Inc. Synthetic, malleable bone graft substitute material
7815826, May 12 2004 Massachusetts Institute of Technology Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like
7828845, Oct 25 2000 Warsaw Orthopedic, Inc. Laterally expanding intervertebral fusion device
7846207, Feb 06 2003 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
7862616, Feb 06 2003 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
8025903, Sep 09 2005 Agnovos Healthcare, LLC Composite bone graft substitute cement and articles produced therefrom
8043377, Sep 02 2006 Osprey Biomedical, Inc. Implantable intervertebral fusion device
8128696, May 11 2005 Mathys AG Bettlach System and implant for ligament reconstruction or bone reconstruction
8153591, Aug 26 2004 PETVIVO HOLDINGS, INC Protein biomaterials and biocoacervates and methods of making and using thereof
8177845, Oct 24 2000 Warsaw Orthopedic, Inc. Osteogenic packing device and method
8177848, Dec 10 1997 Warsaw Orthopedic, Inc. Osteogenic fusion device
8282683, Apr 12 2010 Globus Medical, Inc Expandable vertebral implant
8287538, Jan 14 2008 CONVENTUS ORTHOPAEDICS; CONVENTUS ORTHOPAEDICS, INC Apparatus and methods for fracture repair
8465537, Jun 17 2003 PETVIVO HOLDINGS, INC Encapsulated or coated stent systems
8497236, Feb 13 1998 Zimmer Orthobiologics, Inc. Implantable putty material
8529939, Dec 08 2003 PETVIVO HOLDINGS, INC Mucoadhesive drug delivery devices and methods of making and using thereof
8540774, Nov 16 2007 Depuy Synthes Products, LLC Low profile intervertebral implant
8551525, Dec 23 2010 Bioventus, LLC Bone graft materials and methods
8579908, Sep 26 2003 Depuy Synthes Products, LLC Device for delivering viscous material
8613938, Nov 15 2010 ZIMMER ORTHOBIOLOGICS, INC Bone void fillers
8623393, Apr 29 2002 PETVIVO HOLDINGS, INC Biomatrix structural containment and fixation systems and methods of use thereof
8685102, Dec 10 1997 Warsaw Orthopedic, Inc. Osteogenic fusion device
8685464, Sep 09 2005 Agnovos Healthcare, LLC Composite bone graft substitute cement and articles produced therefrom
8685465, Sep 09 2005 Agnovos Healthcare, LLC Composite bone graft substitute cement and articles produced therefrom
8690874, Dec 22 2000 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
8697107, Apr 27 2012 Warsaw Orthopedic, Inc.; Warsaw Orthopedic, Inc Flowable implant with crosslinkable surface membrane
8709085, Feb 06 2003 Depuy Synthes Products, LLC Intervertebral implant
8715354, Feb 06 2003 Depuy Synthes Products, LLC Intervertebral implant
8721711, Jun 20 2007 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
8721723, Jan 12 2009 Globus Medical, Inc.; Globus Medical, Inc Expandable vertebral prosthesis
8722783, Nov 30 2006 SMITH & NEPHEW UK LIMITED Fiber reinforced composite material
8742072, Dec 21 2006 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
8764831, Feb 06 2003 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
8808255, Dec 12 2008 Oregon Health & Science University Drug delivery cuff
8871267, Sep 25 1998 PETVIVO HOLDINGS, INC Protein matrix materials, devices and methods of making and using thereof
8906022, Mar 08 2010 CONVENTUS ORTHOPAEDICS, INC ; CONVENTUS ORTHOPAEDICS Apparatus and methods for securing a bone implant
8961518, Jan 20 2010 CONVENTUS ORTHOPAEDICS, INC ; CONVENTUS ORTHOPAEDICS Apparatus and methods for bone access and cavity preparation
9000066, Apr 19 2007 SMITH & NEPHEW UK LIMITED Multi-modal shape memory polymers
9005295, Nov 16 2007 DEPUY SYNTHES PRODUCTS, INC Low profile intervertebral implant
9039775, Mar 31 2003 DEPUY SYNTHES PRODUCTS, INC Spinal fixation plates
9060823, Mar 29 2011 Smith & Nephew, Inc Fracture fixation systems having intramedullary support
9107937, Aug 26 2003 PETVIVO HOLDINGS, INC Wound treatments with crosslinked protein amorphous biomaterials
9120919, Dec 23 2003 Smith & Nephew, Inc Tunable segmented polyacetal
9180224, Sep 09 2005 Agnovos Healthcare, LLC Composite bone graft substitute cement and articles produced therefrom
9192419, Nov 07 2008 DEPUY SYNTHES PRODUCTS, INC Zero-profile interbody spacer and coupled plate assembly
9205030, Jul 30 2010 KINKI UNIVERSITY Hard tissue regeneration material and hard tissue regeneration method
9220596, Dec 23 2010 Bioventus, LLC Bone graft materials and methods
9220604, Dec 21 2010 DEPUY SYNTHES PRODUCTS, INC Intervertebral implants, systems, and methods of use
9241809, Dec 21 2010 DEPUY SYNTHES PRODUCTS, INC Intervertebral implants, systems, and methods of use
9308293, Apr 19 2007 Smith & Nephew, Inc. Multi-modal shape memory polymers
9320549, Mar 31 2003 DePuy Synthes Products, Inc. Spinal fixation plates
9402735, Nov 07 2008 DEPUY SYNTHES PRODUCTS, INC Zero-profile interbody spacer and coupled plate assembly
9414935, Nov 07 2008 DePuy Synthes Products, Inc. Zero-profile interbody spacer and coupled plate assembly
9452049, Nov 24 2008 Queensland University of Technology Systems and methods to affect anatomical structures
9463097, Feb 06 2003 DePuy Synthes Products, Inc. Intervertebral implant
9486316, Sep 30 2011 Prime Merger Sub, LLC Osteoconductive implants and methods of using same
9498561, Jul 10 2009 Orthorebirth Co. Ltd.; NAGOYA INSTITUTE OF TECHNOLOGY Fiber wadding for filling bone defects
9517093, Jan 14 2008 Conventus Orthopaedics, Inc. Apparatus and methods for fracture repair
9539104, Sep 30 2011 Prime Merger Sub, LLC Osteoconductive implants and methods of using same
9539365, Jul 10 2009 Orthorebirth Co. Ltd.; NAGOYA INSTITUTE OF TECHNOLOGY Fiber wadding for filling bone defects
9572681, Feb 19 2002 DEPUY SYNTHES PRODUCTS, INC Intervertebral implant
9642658, Oct 15 2008 OrthoClip LLC Device and method for delivery of therapeutic agents via internal implants
9707091, Apr 12 2010 Globus Medical, Inc. Expandable vertebral implant
9730739, Jan 15 2010 Conventus Orthopaedics, Inc. Rotary-rigid orthopaedic rod
9744049, Nov 16 2007 DePuy Synthes Products, Inc. Low profile intervertebral implant
9770534, Apr 19 2007 SMITH & NEPHEW UK LIMITED Graft fixation
9788870, Jan 14 2008 Conventus Orthopaedics, Inc. Apparatus and methods for fracture repair
9795430, Mar 08 2010 Conventus Orthopaedics, Inc. Apparatus and methods for securing a bone implant
9815240, Apr 18 2007 Smith & Nephew, Inc Expansion moulding of shape memory polymers
9848889, Jan 20 2010 Conventus Orthopaedics, Inc. Apparatus and methods for bone access and cavity preparation
9848992, Dec 21 2010 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
9867718, Oct 22 2014 DePuy Orthopaedics, Inc Intervertebral implants, systems, and methods of use
9913735, Apr 12 2010 Globus Medical, Inc. Angling inserter tool for expandable vertebral implant
9924990, Mar 08 2010 Conventus Orthopaedics, Inc. Apparatus and methods for securing a bone implant
9962268, Jan 12 2009 Globus Medical, Inc. Expandable vertebral prosthesis
9993277, Mar 08 2010 Conventus Orthopaedics, Inc. Apparatus and methods for securing a bone implant
9999705, Aug 26 2003 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
Patent Priority Assignee Title
3710789,
3901810,
3938515, Dec 20 1971 ALZA Corporation Novel drug permeable wall
4011602, Oct 06 1975 Battelle Memorial Institute Porous expandable device for attachment to bone tissue
4309488, Jun 23 1978 Battelle-Institut e.V. Implantable bone replacement materials based on calcium phosphate ceramic material in a matrix and process for the production thereof
4550449, Nov 08 1982 DePuy Orthopaedics, Inc Absorbable bone fixation device
4637931, Oct 09 1984 United States of America as represented by the Secretary of the Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
4674488, Mar 04 1985 Baxter International Inc Method of treating bone fractures to reduce formation of fibrous adhesions
4795467, Mar 28 1985 NEUCOLL, INC Xenogeneic collagen/mineral preparations in bone repair
4842604, Dec 19 1985 The Dow Chemical Company Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
4863472, Sep 05 1986 Biocon Oy Bone graft implant
4963145, Jul 09 1983 Sumitomo Cement Co., Ltd. Porous ceramic material and processes for preparing same
5007930, Feb 19 1985 The Dow Chemical Company Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
5024841, Jun 30 1988 ANGIOTECH PHARMACEUTICALS US , INC Collagen wound healing matrices and process for their production
5250584, Aug 31 1988 G-C Dental Industrial Corp. Periodontium-regenerative materials
CH1170001,
DE2815934,
EP11528,
EP295041,
EP321442,
EP349505,
GB2215209,
WO8808305,
WO9013302,
//
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jan 20 1993Laboratorium fur experimentelle ChirurgieSynthesASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0065580643 pdf
May 07 1993Laboratorium fur experimentalle Chirurgie, Forschungsinstitut(assignment on the face of the patent)
Date Maintenance Fee Events
Jun 02 2000ASPN: Payor Number Assigned.
Mar 22 2001ASPN: Payor Number Assigned.
Mar 22 2001M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Mar 31 2001LSM1: Pat Hldr no Longer Claims Small Ent Stat as Indiv Inventor.
Mar 31 2001RMPN: Payer Number De-assigned.
Mar 31 2005M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Apr 20 2009REM: Maintenance Fee Reminder Mailed.
Oct 14 2009EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Oct 14 20004 years fee payment window open
Apr 14 20016 months grace period start (w surcharge)
Oct 14 2001patent expiry (for year 4)
Oct 14 20032 years to revive unintentionally abandoned end. (for year 4)
Oct 14 20048 years fee payment window open
Apr 14 20056 months grace period start (w surcharge)
Oct 14 2005patent expiry (for year 8)
Oct 14 20072 years to revive unintentionally abandoned end. (for year 8)
Oct 14 200812 years fee payment window open
Apr 14 20096 months grace period start (w surcharge)
Oct 14 2009patent expiry (for year 12)
Oct 14 20112 years to revive unintentionally abandoned end. (for year 12)